This site is intended for Healthcare professionals only.
×

Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash


Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash

Merck Inc’s lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.

New Delhi: Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company’s renal cancer drug candidate.

The company’s lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.

Peloton shareholders will be eligible to receive a further $1.15 billion on achieving certain milestones.

Read Also: Merck will now be called Procter & Gamble Health

The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week.

Credit Suisse acted as a financial adviser for Merck and Covington & Burling LLP as its legal adviser. Centerview Partners was a financial adviser to Peloton and Wilson Sonsini Goodrich & Rosati was its legal adviser.


Source: Reuters
0 comment(s) on Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted